Nurix Therapeutics. has filed a patent for bifunctional compounds that act as HPK1 degraders through the ubiquitin proteasome pathway. These compounds offer a method for treating diseases influenced by HPK1. GlobalData’s report on Nurix Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Nurix Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Nurix Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Nurix Therapeutics's grant share as of January 2024 was 5%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20240025923A1) discloses a compound with a specific structure (Formula Ib) and its use in pharmaceutical compositions. The compound is designed to target increased hematopoietic progenitor kinase 1 (HPK1) activity, which is associated with certain diseases and disorders. The patent claims cover methods of treating diseases related to HPK1 activity, increasing T-cell activation, treating cancer, and inhibiting the growth of cancer cells by administering the compound. Additionally, the patent application includes combinations with other therapeutic agents to enhance the effectiveness of the treatment.

The compound described in the patent application shows promise in targeting HPK1 activity and treating various diseases, including cancer. The methods outlined in the claims provide a detailed framework for administering the compound to patients in need of treatment. Furthermore, the inclusion of additional therapeutic agents in combination with the compound demonstrates a comprehensive approach to addressing complex medical conditions. Overall, the patent application highlights the potential of the compound in therapeutic interventions and sets the stage for further research and development in the field of pharmaceuticals and cancer treatment.

To know more about GlobalData’s detailed insights on Nurix Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies